DavidJohnKuterMDDRPHIL

PubMed

• 168 citations
  The biology of thrombopoietin and thrombopoietin receptor agonists
  David J. Kuter
  International Journal of Hematology. 2013-07-03
• 259 citations
  Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.
  David J. Kuter, C. Glenn Begley
  Blood. 2002-11-15
• 1568 citations
  International consensus report on the investigation and management of primary immune thrombocytopenia.
  Drew Provan, Roberto Stasi, Adrian C. Newland, Victor S. Blanchette, Paula H. B. Bolton-Maggs
  Blood Advances. 2010-01-14

Journal Articles

• Romiplostim in Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia (ITP) for up to 1 Year and in Those with Chronic ITP for More Than 1 Year: A S...  
  David J Kuter, Bhakti Mehta, British Journal of Haematology
• Presenting Signs and Patient Co‐Variables in Gaucher Disease: Outcome of the Gaucher Early Diagnosis Consensus (GED‐C) Delphi Initiative  
  David J Kuter, Neal J Weinreb, Internal Medicine Journal

Abstracts/Posters

• Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
  David J. Kuter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies 
  American Thoracic Society, 2013 International Conference, Philadelphia, Pennsylvania, USA
• Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies 
  2013 International Conference, Philadelphia, Pennsylvania, USA
• Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based Considerations 
  Harvard Medical School, Boston, Massachusetts - 9/30/2012
• Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based Considerations 
  Harvard Medical School ,Department Of Continuing Education, Cambridge, Massachusetts - 6/10/2013
• Join now to see all

Other

• Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based Considerations 
  David Kuter, MD, Haematologica
  https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
  UpToDate, Wolters Kluwer Health - 2012-07-24
• Infections and Vaccination in Hereditary Hemorrhagic Telangiectasia: Microbiological Evidence-Based Considerations 
  David Kuter, MD, Haematologica
  https://www.doximity.com/articles/316713ed-d3e2-47da-8487-94d0db6754ab
  UpToDate, Wolters Kluwer Health - 2013-01-30
• Avatrombopag, an Oral Thrombopoietin Receptor Agonist: Results of Two Double‐Blind, Dose‐Rising, Placebo‐Controlled Phase 1 Studies 
  David Kuter, MD, British Journal of Haematology
  https://www.doximity.com/articles/d909d298-5043-4c91-b3f6-84a999dd1fef
  UpToDate, Wolters Kluwer Health - 2012-09-07